• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

恶性胸膜间皮瘤的局部治疗和肿瘤周围基质的调控:一种转化方法。

Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach.

机构信息

Cell Therapy Production Unit-UPTC and Cerebrovascular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, 20133 Milan, Italy.

Unit of Respiratory Diseases, Department of Medical Sciences and Infective Diseases, IRCCS Policlinico San Matteo Foundation and University of Pavia Medical School, 27100 Pavia, Italy.

出版信息

Int J Mol Sci. 2021 Aug 20;22(16):9014. doi: 10.3390/ijms22169014.

DOI:10.3390/ijms22169014
PMID:34445720
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8396500/
Abstract

Malignant Pleural Mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated with asbestos exposure and still lacking effective therapies. Modern targeted biological strategies that have revolutionized the therapy of other solid tumors have not had success so far in the MPM. Combination immunotherapy might achieve better results over chemotherapy alone, but there is still a need for more effective therapeutic approaches. Based on the peculiar disease features of MPM, several strategies for local therapeutic delivery have been developed over the past years. The common rationale of these approaches is: (i) to reduce the risk of drug inactivation before reaching the target tumor cells; (ii) to increase the concentration of active drugs in the tumor micro-environment and their bioavailability; (iii) to reduce toxic effects on normal, non-transformed cells, because of much lower drug doses than those used for systemic chemotherapy. The complex interactions between drugs and the local immune-inflammatory micro-environment modulate the subsequent clinical response. In this perspective, the main interest is currently addressed to the development of local drug delivery platforms, both cell therapy and engineered nanotools. We here propose a review aimed at deep investigation of the biologic effects of the current local therapies for MPM, including cell therapies, and the mechanisms of interaction with the tumor micro-environment.

摘要

恶性胸膜间皮瘤(MPM)是一种罕见且侵袭性的胸膜间皮瘤,主要与石棉暴露有关,目前仍缺乏有效的治疗方法。现代靶向生物策略已经彻底改变了其他实体瘤的治疗方法,但迄今为止在 MPM 中尚未取得成功。联合免疫疗法可能比单独化疗取得更好的效果,但仍需要更有效的治疗方法。基于 MPM 的特殊疾病特征,过去几年已经开发了几种局部治疗药物输送策略。这些方法的共同原理是:(i)降低药物在到达靶肿瘤细胞之前失活的风险;(ii)增加肿瘤微环境中活性药物的浓度及其生物利用度;(iii)降低对正常非转化细胞的毒性作用,因为药物剂量远低于全身化疗。药物与局部免疫炎症微环境之间的复杂相互作用调节了随后的临床反应。在这方面,目前的主要关注点是开发局部药物输送平台,包括细胞疗法和工程纳米工具。在这里,我们提出了一项旨在深入研究当前用于 MPM 的局部治疗方法(包括细胞疗法)的生物学效应及其与肿瘤微环境相互作用的机制的综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9470/8396500/3cc71b412914/ijms-22-09014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9470/8396500/eeffcaf1b928/ijms-22-09014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9470/8396500/3cc71b412914/ijms-22-09014-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9470/8396500/eeffcaf1b928/ijms-22-09014-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9470/8396500/3cc71b412914/ijms-22-09014-g002.jpg

相似文献

1
Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach.恶性胸膜间皮瘤的局部治疗和肿瘤周围基质的调控:一种转化方法。
Int J Mol Sci. 2021 Aug 20;22(16):9014. doi: 10.3390/ijms22169014.
2
Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.胸膜间皮瘤的免疫治疗:当前和新兴的治疗策略。
Int J Mol Sci. 2024 Oct 9;25(19):10861. doi: 10.3390/ijms251910861.
3
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).SEOM 临床指南:恶性胸膜间皮瘤的治疗(2020 年)。
Clin Transl Oncol. 2021 May;23(5):980-987. doi: 10.1007/s12094-020-02532-2. Epub 2021 Feb 4.
4
Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.恶性胸膜间皮瘤:最新技术与先进细胞疗法
Eur J Med Chem. 2017 Dec 15;142:266-270. doi: 10.1016/j.ejmech.2017.07.063. Epub 2017 Aug 2.
5
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.恶性胸膜间皮瘤中的免疫反应和免疫治疗干预。
Cancer Immunol Immunother. 2011 Nov;60(11):1509-27. doi: 10.1007/s00262-011-1103-6. Epub 2011 Sep 13.
6
Emerging biological therapies for the treatment of malignant pleural mesothelioma.新兴的生物疗法治疗恶性胸膜间皮瘤。
Expert Opin Emerg Drugs. 2021 Jun;26(2):179-192. doi: 10.1080/14728214.2021.1924670. Epub 2021 May 17.
7
New therapeutic strategies for malignant pleural mesothelioma.恶性胸膜间皮瘤的新治疗策略
Biochem Pharmacol. 2017 Jan 1;123:8-18. doi: 10.1016/j.bcp.2016.07.012. Epub 2016 Jul 16.
8
Updates in Staging and Management of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤分期与治疗进展。
Surg Oncol Clin N Am. 2020 Oct;29(4):603-612. doi: 10.1016/j.soc.2020.06.002. Epub 2020 Aug 10.
9
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.载培美曲塞纳米粒靶向恶性胸膜间皮瘤细胞的体外研究。
Int J Nanomedicine. 2019 Jan 23;14:773-785. doi: 10.2147/IJN.S186344. eCollection 2019.
10
Treatment of malignant pleural mesothelioma: current status and future directions.恶性胸膜间皮瘤的治疗:现状与未来方向
Monaldi Arch Chest Dis. 2010 Jun;73(2):79-85. doi: 10.4081/monaldi.2010.302.

引用本文的文献

1
Extracellular vesicles isolated from adipose tissue-derived mesenchymal stromal cells as carriers for Paclitaxel delivery.从脂肪组织来源的间充质基质细胞中分离的细胞外囊泡作为紫杉醇递送载体。
Stem Cell Res Ther. 2025 Jun 15;16(1):307. doi: 10.1186/s13287-025-04435-x.
2
Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.改善胸膜间皮瘤治疗的治疗策略
Curr Med Chem. 2025;32(11):2093-2114. doi: 10.2174/0109298673268206240405084558.
3
Smart Sensors and Microtechnologies in the Precision Medicine Approach against Lung Cancer.

本文引用的文献

1
Biomaterial scaffold-based local drug delivery systems for cancer immunotherapy.用于癌症免疫治疗的基于生物材料支架的局部药物递送系统。
Sci Bull (Beijing). 2020 Sep 15;65(17):1489-1504. doi: 10.1016/j.scib.2020.04.012. Epub 2020 Apr 9.
2
Immunotherapy in malignant pleural mesothelioma: a review of literature data.恶性胸膜间皮瘤的免疫治疗:文献数据综述
Transl Lung Cancer Res. 2021 Jun;10(6):2988-3000. doi: 10.21037/tlcr-20-673.
3
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review.恶性胸膜间皮瘤的免疫微环境:文献综述
精准医学对抗肺癌中的智能传感器与微技术
Pharmaceuticals (Basel). 2023 Jul 22;16(7):1042. doi: 10.3390/ph16071042.
4
Extracellular Vesicles Isolated from Malignant Mesothelioma Cancer-Associated Fibroblasts Induce Pro-Oncogenic Changes in Healthy Mesothelial Cells.从恶性间皮瘤癌症相关成纤维细胞中分离出的细胞外囊泡诱导健康间皮细胞发生致癌变化。
Int J Mol Sci. 2022 Oct 18;23(20):12469. doi: 10.3390/ijms232012469.
5
Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience.广泛胸膜切除术/剥除术治疗恶性胸膜间皮瘤的可行性和安全性。单一组经验。
Thorac Cancer. 2022 Oct;13(19):2792-2798. doi: 10.1111/1759-7714.14627. Epub 2022 Sep 2.
6
Immunological Responses to Cancer Therapy.癌症治疗的免疫反应。
Int J Mol Sci. 2022 Jun 23;23(13):6989. doi: 10.3390/ijms23136989.
7
Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.间皮瘤治疗的新见解:新兴途径与未来前景
Front Oncol. 2022 Jun 17;12:916839. doi: 10.3389/fonc.2022.916839. eCollection 2022.
Cancers (Basel). 2021 Jun 26;13(13):3205. doi: 10.3390/cancers13133205.
4
Immunotherapeutic Approaches in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的免疫治疗方法
Cancers (Basel). 2021 Jun 4;13(11):2793. doi: 10.3390/cancers13112793.
5
Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations.恶性胸膜间皮瘤的分子指纹图谱:不仅仅是基因改变的问题。
J Clin Med. 2021 Jun 2;10(11):2470. doi: 10.3390/jcm10112470.
6
Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤的免疫微环境与遗传学
Front Oncol. 2021 Jun 11;11:684025. doi: 10.3389/fonc.2021.684025. eCollection 2021.
7
Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤中肿瘤免疫微环境(TIME)的病理特征
Cancers (Basel). 2021 May 24;13(11):2564. doi: 10.3390/cancers13112564.
8
Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials.三项I/II期试验中接受树突状细胞疗法治疗的间皮瘤患者的长期随访
Vaccines (Basel). 2021 May 19;9(5):525. doi: 10.3390/vaccines9050525.
9
Old Borders and New Horizons in Multimodality Imaging of Malignant Pleural Mesothelioma.恶性胸膜间皮瘤多模态成像的旧边界和新视野。
Thorac Cardiovasc Surg. 2022 Dec;70(8):677-683. doi: 10.1055/s-0041-1728714. Epub 2021 Jun 1.
10
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.嵌合抗原受体 T 细胞疗法治疗胸膜间皮瘤:原理、临床前开发和临床试验。
Lung Cancer. 2021 Jul;157:48-59. doi: 10.1016/j.lungcan.2021.05.004. Epub 2021 May 5.